XNAS · HRMY
+0.34% · +$0.1300 · Vol 607.9K
Market closed · last close 4:00 PM ET · price as of 16:30:23 ET
Harmony Biosciences Holdings, Inc. Common Stock

Harmony Biosciences Holdings, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$38.21
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is HRMY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for HRMY are being assembled.
About Harmony Biosciences Holdings, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
293
Country
US

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$37.96
Day high
$38.49
Day low
$37.36
Previous close
$38.08
52W high
$38.49
-0.73% from high
52W low
$33.21
95% of range
Market cap
$2.2B
P/E
13.27×
EPS
$2.88
Shares out
57.9M
Volume
607.9K
VWAP
$37.91
Price history computed in-house
1W
+2.36%
1M
+7.76%
SMA 50 $35.43 · above
SMA 200 $35.43 · above
52W position 95%
Veridion warehouse edge

Warehouse intelligence for HRMY.

Veridion Score
82
0: 851: 472: 713: 704: 695: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

HRMY insider activity

Harmony Biosciences Holdings, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for HRMY.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

HRMY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for HRMY in this window.
Lobbying spend

HRMY lobbying filings, year to date.

Registered lobbying filings matched to Harmony Biosciences Holdings, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for HRMY in this window.
Latest news · HRMY
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for HRMY.
Options
Sovereign unlock shows live options positioning for HRMY.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.